A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

June 18, 2024

Study Completion Date

June 21, 2024

Conditions

Autism Spectrum DisorderAutism

Interventions

DRUG

L1-79

tyrosine hydroxylase inhibitor

Trial Locations (8)

Center for Autism and The Developing Brain, White Plains

Ohio State University, Columbus

Rush University, Chicago

Thompson Center for Autism and Neurodevelopmental Disorders, Columbia

Red Oak Psychiatry Associates, Houston

Southwest Autism Research and Resource Center, Phoenix

Thompson Autism Center CHOC, Orange

Cortica, San Rafael

All Listed Sponsors

lead

Yamo Pharmaceuticals LLC

INDUSTRY